Gene · 974
Papers4,161
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
601 to 620 of 4,161
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| The Metabolism and Immune Environment in Diffuse Large B-Cell Lymphoma. | Metabolites | 2023 | 37367892 | PubTator, text mining | PubMed |
| A nomogram for predicting the rapid progression of diffuse large B-cell lymphoma established by combining baseline PET/CT total metabolic tumor volume, lesion diffusion, and TP53 mutations. | Cancer Med | 2023 | 37366281 | PubTator, text mining | PubMed |
| Phase I Study of Acalabrutinib Plus Danvatirsen (AZD9150) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma Including Circulating Tumor DNA Biomarker Assessment. | Clin Cancer Res | 2023 | 37364001 | PubTator, text mining | PubMed |
| Documenting the immune response in patients with COVID-19-induced acute respiratory distress syndrome. | Front Cell Dev Biol | 2023 | 37363730 | PubTator, text mining | PubMed |
| Engineering B cells with customized therapeutic responses using a synthetic circuit. | Mol Ther Nucleic Acids | 2023 | 37359346 | PubTator, text mining | PubMed |
| [Clinicopathologic characteristics and prognostic analysis of testicular diffuse large B-cell lymphoma]. | Zhonghua Xue Ye Xue Za Zhi | 2023 | 37357002 | PubTator, text mining | PubMed |
| [Current researches and progresses on new antibody drugs in the treatment of relapsed/refractory diffuse large B-cell lymphoma]. | Zhonghua Xue Ye Xue Za Zhi | 2023 | 37356992 | PubTator, text mining | PubMed |
| [Combination of zanubrutinib and rituximab in the treatment of primary cutaneous diffuse large B-cell lymphoma leg type with CD79B and MYD88 mutations: a case report]. | Zhonghua Xue Ye Xue Za Zhi | 2023 | 37356991 | PubTator, text mining | PubMed |
| [Chinese consensus on minimal residual disease detection and interpretation of patients with chronic lymphocytic leukemia (2023)]. | Zhonghua Xue Ye Xue Za Zhi | 2023 | 37356978 | PubTator, text mining | PubMed |
| [Chinese expert consensus on the diagnosis and management of intravascular large B cell lymphoma (2023)]. | Zhonghua Xue Ye Xue Za Zhi | 2023 | 37356977 | PubTator, text mining | PubMed |
| Microtubule stabilization targeting regenerative chondrocyte cluster for cartilage regeneration. | Theranostics | 2023 | 37351173 | PubTator, text mining | PubMed |
BeEAM (Bendamustine, Etoposide, Cytarabine, Melphalan) Versus BEAM (Carmustine, Etoposide, Cytarabine, Melphalan) as Conditioning Regimen Before Autologous Haematopoietic Cell Transplantation: A Systematic Review and Meta-Analysis. | Cell Transplant | 2023 | 37350429 | PubTator, text mining | PubMed |
| High-dimensional single-cell analysis unveils distinct immune signatures of peripheral blood in patients with pancreatic ductal adenocarcinoma. | Front Endocrinol (Lausanne) | 2023 | 37347110 | PubTator, text mining | PubMed |
| Exploratory Genome-Wide Association Analysis to Identify Pharmacogenetic Determinants of Response to R-CHOP in Diffuse Large B-Cell Lymphoma. | Cancers (Basel) | 2023 | 37345090 | PubTator, text mining | PubMed |
| B-cell-specific checkpoint molecules that regulate anti-tumour immunity. | Nature | 2023 | 37344597 | PubTator, text mining | PubMed |
| Selective oxidative protection leads to tissue topological changes orchestrated by macrophage during ulcerative colitis. | Nat Commun | 2023 | 37344477 | PubTator, text mining | PubMed |
| Role of RNA Splicing Mutations in Diffuse Large B Cell Lymphoma. | Int J Gen Med | 2023 | 37342407 | PubTator, text mining | PubMed |
| The current advances of lncRNAs in breast cancer immunobiology research. | Front Immunol | 2023 | 37342324 | PubTator, text mining | PubMed |
| Lactation-associated macrophages exist in murine mammary tissue and human milk. | Nat Immunol | 2023 | 37337103 | PubTator, text mining | PubMed |
| Exploration of the impact of multimode thermal therapy versus radiofrequency ablation on CD8+ T effector cells of liver malignancies based on single cell transcriptomics. | Front Immunol | 2023 | 37334386 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/974/papers?page=31